- Home
- RAVE vs XOMAP Comparison
RAVE vs XOMAP Comparison
Compare RAVE & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAVE
- XOMAP
- Stock Information
- Founded
- RAVE 1958
- XOMAP N/A
- Country
- RAVE United States
- XOMAP United States
- Employees
- RAVE N/A
- XOMAP 13
- Industry
- RAVE Restaurants
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- RAVE Consumer Discretionary
- XOMAP Health Care
- Exchange
- RAVE Nasdaq
- XOMAP Nasdaq
- Market Cap
- RAVE N/A
- XOMAP N/A
- IPO Year
- RAVE N/A
- XOMAP N/A
- Fundamental
- Price
- RAVE $2.43
- XOMAP $25.50
- Analyst Decision
- RAVE
- XOMAP
- Analyst Count
- RAVE 0
- XOMAP 0
- Target Price
- RAVE N/A
- XOMAP N/A
- AVG Volume (30 Days)
- RAVE 17.1K
- XOMAP N/A
- Earning Date
- RAVE 05-01-2025
- XOMAP N/A
- Dividend Yield
- RAVE N/A
- XOMAP N/A
- EPS Growth
- RAVE 37.66
- XOMAP N/A
- EPS
- RAVE 0.18
- XOMAP N/A
- Revenue
- RAVE $12,236,000.00
- XOMAP N/A
- Revenue This Year
- RAVE N/A
- XOMAP N/A
- Revenue Next Year
- RAVE N/A
- XOMAP N/A
- P/E Ratio
- RAVE $13.92
- XOMAP N/A
- Revenue Growth
- RAVE 3.25
- XOMAP N/A
- 52 Week Low
- RAVE $1.70
- XOMAP N/A
- 52 Week High
- RAVE $3.36
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- RAVE 36.68
- XOMAP 43.38
- Support Level
- RAVE $2.44
- XOMAP $25.00
- Resistance Level
- RAVE $3.10
- XOMAP $26.09
- Average True Range (ATR)
- RAVE 0.13
- XOMAP 0.14
- MACD
- RAVE -0.04
- XOMAP 0.00
- Stochastic Oscillator
- RAVE 11.90
- XOMAP 45.87
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.